Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02451748 · ClinicalTrials.gov registry record · Phase 4
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
A Phase 4 study of Rheumatoid Arthritis, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT02451748: Completed Phase 4 study of Rheumatoid Arthritis, sponsored by University of Illinois at Chicago.
NCT02451748 is a Phase 4 study of Rheumatoid Arthritis that has completed, run by University of Illinois at Chicago. The registered enrollment target is 32 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02451748, a Phase 4 study of Rheumatoid Arthritis, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis. Knowledge gained from this study may lead to new and better therapies for arthritis.
Primary Outcome
Expression of IL-7 and IL-7R mRNA levels measured by real-time RT-PCR.
Conditions Studied
Interventions
- DRUG Hydroxychloroquine
- DRUG Sulfasalazine
- OTHER Lab Work
- DRUG Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
- DRUG Certolizumab pegol (CDP870, tradename Cimzia)
Study Locations (1)
Illinois
- Outpatient Care Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-12 |
| Phase | Phase 4 |
What the finished NCT02451748 record still lists
NCT02451748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 5 interventions - of which Hydroxychloroquine is the first listed.
NCT02451748 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT02451748 about?
NCT02451748 is a clinical study titled "IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA". The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis. Knowledge gained from this study may lead to new and better therapies for arthritis.
What is the current status of trial NCT02451748?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2015-08. Estimated completion is 2017-12.
What conditions does trial NCT02451748 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT02451748?
The interventions under investigation include: Hydroxychloroquine (DRUG), Sulfasalazine (DRUG), Lab Work (OTHER), Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg) (DRUG), Certolizumab pegol (CDP870, tradename Cimzia) (DRUG).
Who is sponsoring clinical trial NCT02451748?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02451748 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02451748's enrollment target sits among peer trials
32 156th of 197 higher than 40 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NSAIDs vs. Coxibs in the Presence of Aspirin
RECRUITING · Phase 4
-
Improving Bone Health Among Rheumatoid Arthritis (RA) Patients on Chronic Glucocorticoids
COMPLETED · Phase 4
-
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
COMPLETED · Phase 4
-
Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
COMPLETED · Phase 4
-
A Study of Baricitinib in Participants With Rheumatoid Arthritis
COMPLETED · Phase 4
-
Centocor Microarray Study of Patients
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia